Article Sidebar
Published:
Dec 5, 2018DOI:
10.4314/jpb.v15i2.13Keywords:
Article Details
Copyright of articles published shall reside exclusively with the Faculty of Pharmaceutical Sciences, University of Jos.
DECLARATION & COPYRIGHT TRANSFER
I/We the undersigned author(s) of article entitled
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
Declare as follows:
- The manuscript submitted to Journal of Pharmacy & Bioresources is original and has not been and will be published, whole or in part, in print or electronic format, in any other journal. It is also not being currently considered for publication in any journal.
- The submitted manuscript is a joint decision of all the coauthors.
- Each author has participated sufficiently in the work to warrant his or her inclusion in the list of authors. To this end, each author takes responsibility for appropriate portions of the manuscript.
- Authors have obtained necessary approval to carry out the experiments on animals and human subjects. Approval certificates will be furnished, if required by publishers or editors of the journal.
- Authors do not have any conflict of interest (financial or otherwise) other than those declared.
- If the manuscript is accepted for publication, the authors transfer and assign copyright of the article referenced above to Journal of Pharmacy and Bioresources.
Name & Signature of authors
1. 2.
- 4.
- 6.
- 8.
Corresponding authors name address, affiliation and email:
Main Article Content
Effect of fixed-dose sizes on in vitro properties of artemether-lumefantrine tablets
Abstract
The World Health Organization recommends artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. Artemether-lumefantrine (A-L) is a fixed-dose combination (FDC) of two active antimalarial ingredients. Pharmaceutical equivalence (PE) of three FDC: Coartem® (20/120 mg); B (40/240 mg) and C (80/480 mg) were investigated. Assay was performed for A-L separately with a validated HPLC method. Assay for artemether in Coartem®, B and C were 93.34%, 98.27% and 100.78% while for lumefantrine 96.44 %, 97.34 % and 93.52 % respectively were obtained. From the dissolution test, the mean percent of artemether released after 1 h for Coartem®, B, and C were 38.67%, 32.86% and 50.74% respectively. Lumefantrine after 45mins gave 93.89%, 64.39% and 64.76% respectively. The data obtained were compared using ANOVA which was not statistically significant (P>0.05). The f2 values for B & C was greater than 50 suggesting their similarity with Coartem®. The focus of this study is to evaluate their in vitro properties and their overall performance.
Keywords: Artemether-lumefantrine tablets; Fixed-dose combination; Pharmaceutical equivalence; Antimalarial
